Pure Global
NCT06232122

Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer

Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer With CA125 Elevation From Complete Response After Therapy
Chang Gung Memorial Hospital·ClinicalTrials.gov·diagnostic testRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Ovarian Cancer
Drug/Device/Intervention
68Ga-FAPI-46
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Chang Gung Memorial Hospital
Location
Taoyuan City, Taiwan
Timeline & enrollment
Phase
N/A
Start date
Aug 01, 2022
End date
Jul 31, 2028
Enrollment
45 participants
Primary outcome

Diagnostic performances of 68Ga-FAPI and 18F-FDG PET/CT for ovarian cancer recurrence after one year from PET/CT imaging in Per-Protocol Analysis Dataset

Summary

A prospective cohort imaging study in a single institution to evaluate 68Ga- FAPI-46 and
 18F-FDG PET/CT imaging for detecting recurrent tumor lesions in patients of ovarian cancer
 with CA125 elevation from complete response after therapy

ICD-10 classifications
Malignant neoplasm of ovarySecondary malignant neoplasm of ovaryBenign neoplasm of ovaryOvarian pregnancyOvarian dysfunction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06232122
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06232122 through Pure Global AI's free database. This phase not specified trial is sponsored by Chang Gung Memorial Hospital and is currently Recruiting. The study focuses on Ovarian Cancer. Target enrollment is 45 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.